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Abstract
2,2-Dialkylglycine Decarboxylase, DGD, is a decarboxylating transaminase that 
is dependent on a vitamin B6 cofactor, pyridoxal 5’-phosphate (PLP). DGD catalyzes the 
decomposition of 2-methylalanine in two steps. DGD was purified by ammonium sulfate 
precipitation and ion-exchange chromatography. The enzyme was reduced to form a 
covalent bond between the enzyme and the PLP. Also, a-(Trifluoromethyl) Alanine, a 
suicide mechanism based inhibitor was reacted with DGD until the enzyme was 
completely inactivated. The nonmodified DGD and these two modified forms of the 
enzyme were subjected to enzymatic digestion by trypsin. Finally, all three peptide 
mixtures were analyzed by LC/MS/MS. The mass spectra confirmed the amino acid 
sequence as predicted by the nucleotides of the gene, and the covalent attachment of the 
cofactor to lysine 272.
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1Chapter 1 - Literature Review 
Part I - 2,2-Dialkylglvcine Decarboxylase (DGD) 
1.1 Purpose of the Project
The question addressed by this project was: “can we use mass spectroscopy to verify 
the location of the B6 cofactor, pyridoxal 5'-phosphate (PLP) cofactor and the amino acid 
sequence of 2,2-dialkylglycine decarboxylase (DGD)”? The approach used to answer 
this question was to digest unmodified and modified DGD with trypsin. Then, 
LC/MS/MS was used to compare covalently modified (PLP or trifluoroaminoisobutyrate, 
F3AIB) enzyme with the unmodified enzyme enabling the identification of the peptide of 
interaction. Based on the results of the LC/MS/MS, one can determine whether or not the 
inhibitor binding site is the same as the PLP binding site.
The reason that DGD was utilized in this project is because it is a unique in its ability 
to decarboxylate and transaminate amino acid substrates. Since, DGD is a well studied 
enzyme it is useful because the results of the amino acid content found by LC/MS/MS 
can be compared with the known sequence.
1.2 Introduction to 2,2-Dialkylglycine Decarboxylase (DGD)
The enzyme 2,2-dialkylglycine decarboxylase (DGD), was first isolated from the soil 
bacterium, Pseudomonas cepacia, in 1964.(7) DGD is a decarboxylating transaminase 
that is dependent on a vitamin B6 cofactor, pyridoxal 5’-phosphate (PLP). One of the
normal substrates for DGD is 2-methylalanine. The biological role for DGD is unclear; 
however, it is known that the substrates for DGD, 2-methylalanine and isovaline, are 
found in cytotoxic peptides that are produced by soil fungi. These substrates are also 
found in organic components of carbonaceous meteorites; 2-methylalanine and isovaline 
have been found in an iridium rich Cretaceous-Tertiary boundary layer which is 
associated with ancient bolide impacts on earth. This enzyme catalyzes the 
decomposition reaction of 2-methylalanine in two steps. First, the amino acid forms a 
covalent aldimine intermediate between the a-amino group of the amino acid and the 
PLP. Carbon dioxide and a ketone are released upon the transfer of the amino group to 
the cofactor, PLP, resulting in formation of an enzyme bound pyridoxamine 5’-phosphate 
(PMP) form of the cofactor. Then, amino transfer from the cofactor to the pyruvate 
results in the formation of L-alanine and regeneration of the cofactor in the PLP form 
(Figure 1.1).
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Figure 1.1 -  Reactions of DGD.
1.3 2-Methylalanine Metabolism by Soil Bacteria
In 1964, a soil bacterium was found that metabolized 2-methylalanine to form carbon 
dioxide and acetone.(2) The formation of carbon dioxide in the presence of pyruvate was 
dependent on pyridoxal 5’-phosphate (PLP). To study this phenomenon Aaslestad and 
Larson grew bacteria on medium containing 2-methylalanine as the sole nitrogen source. 
They found that this bacterium did grow on the 2-methylalanine with carbon dioxide, 
acetone and alanine formed as products. Isopropylamine, expected to be the product of 
normal amino acid decarboxylation, was not found. The optimal pH for the 
decarboxylation reaction was found to be 7.8, and at this pH 62% of the substrate was
decarboxylated. The authors proposed an enzymatic mechanism for this reaction via the 
formation of a Schiff base. First, a Schiff base would form between the 2-methylalanine 
and the cofactor, PLP. Then, the amino acid is decarboxylated and the substrate-cofactor 
complex is directed to one of two stable Schiff base structures. One structure would form 
an amine, isopropylamine, and the aldehyde form of the cofactor upon hydrolysis. The 
other structure would form a keto compound, acetone, and the amine form of the cofactor 
upon hydrolysis. Since the authors did not detect any free isopropylamine during the 
metabolism of 2-methylalanine nor did Keller and O’Leary (3), the first structure 
mentioned above seemed unlikely. These experiments support the formation of a keto 
compound, acetone, and the amine form of the cofactor upon hydrolysis since the 
formation of acetone was detected.
In 1969, it was shown that soil bacteria that utilize a-aminoisobutyrate (AIB) as a 
sole nitrogen source can possibly decarboxylate the AIB via two types of decarboxylation 
reactions (Figure 12).{4) One type of decarboxylation is direct decarboxylation to form 
carbon dioxide and isopropylamine. The second is decarboxylation to form carbon 
dioxide and acetone while transaminating the pyridoxal to pyridoxamine. This type of 
decarboxylation was termed “decarboxylation-dependent transamination” by Kalyankar 
and Snell in 1962. Dempsey found that AIB metabolism of bacteria is via the 
“decarboxylation-dependent transamination” and not via the direct decarboxylation. One 
reason for this conclusion was that there was a stoichiomeric release of carbon dioxide 
and acetone from the bacteria. Also, carbon dioxide release from the organism required 
the presence of pyruvate. For a direct decarboxylation reaction to occur, one enzyme is
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required to decarboxylate the AIB and another enzyme would be required to oxidize the 
amine to convert the nitrogen to a form that can be used by the bacteria. However, only 
one enzyme is required for the “decarboxylation-dependent transamination”. This is 
because one enzyme converts the AIB to a nitrogen available form of L-alanine. Thus, it 
was concluded that this enzyme does not decarboxylate by direct decarboxylation. This 
finding agreed with the conclusion of Aaslestad and Larson in 1964.
Decarboxylation Dependent Transamination
CH.
h3C- -c o 2h +
NH, h 3c  c o 2h
H X - -c o 2h + co2 +
NH, h3c  c h 3
Direct Decarboxylation
CH3 NH,
H X - - c o 2h CO, H X - -C 02H
NH, HX" X H 3 NH,
Figure 1.2 -  Proposed mechanisms of AIB decarboxylation.
1.4 Characterization of DGD
In 1970, Bailey, Chotamangsa, and Vuttive showed that the mechanism of 
a-dialkylamino acid transaminase supported the Dunathan hypothesis.(5, 6) The 
Dunathan hypothesis explains how an enzyme uses the rotation of a substrate to control 
which group bound to an amino acid a-carbon is cleaved. The amino acid bound PLP 
aldimine is oriented in an activated position so that the bond to be cleaved is 
perpendicular to the plane of the PLP ring. Dunathan suggested that the orientation could 
be directed by the binding of the substrate to the a-carboxylate, which is in the active site 
of the enzyme. An active site residue that is positively charged can form a salt bridge 
with the carboxylate of the amino acid that is bound to the PLP. If this happens the 
enzyme can restrict the rotation about the a-carbon to the nitrogen bond thus holding the 
group to be cleaved in the perpendicular position (5, 7). Experiments were performed 
that analyzed the transamination of D-alanine and L-alanine. When D-alanine was the 
substrate, decarboxylation occurred prior to transamination. However, when L-alanine 
was the substrate the hydrogen is located in the position to be cleaved thus no 
decarboxylation occurs. This implies that amino acids are oriented by binding of the 
methyl group. Thus, it was concluded that there is a single orientation of the 
a-dialkylamino acid transaminase active site that leads to the cleavage of the a-carbon 
otherwise there would have been decarboxylation of the L-alanine.
In 1971, Lamartiniere et al. isolated a-dialkylamino acid transaminase, the enzyme 
that catalyzes the decarboxylation-dependent transamination metabolism of 
2-methylalanine, from Pseudomonas cepacia and the molecular weight of this enzyme
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was determined to be 47,000 Da.(S) They looked among several previously isolated 
strains of bacteria that showed the enzymatic activity to find a more stable enzyme than 
the one isolated by Dempsey in 1969. All the bacteria were all grown, harvested, 
disrupted by sonic oscillation, centrifuged, and purified by ammonium sulfate 
fractionations. The ammonium sulfate fractions were dialyzed for one week and the 
fractions were assayed for enzymatic activity. It was shown that the Pseudomonas 
cepacia enzyme retained 78% of its activity over one week, and the specific activity of 
this enzyme was higher than the specific activity of the enzyme isolated by Dempsey in 
1969. It was found that sodium pyruvate is a competitive inhibitor of the PLP form of 
a-dialkylamino acid transaminase with a K, of 5 mM. The molecular weight of the 
enzyme was found to be 188,000 Da by sedimentation equilibrium analysis. An average 
value of 47,000 Da was found when the sedimentation equilibrium analysis was 
performed in the presence of 8 M urea and 7 M guanidine HC1. These results suggest 
that the native enzyme consisted of four subunits thus a-dialkylamino acid transaminase 
appeared to be a tetramer. However, results obtained from a tryptic map generated by 
two dimensional chromatography of the tryptic digest of the enzyme suggested that there 
were eight subunits. There was no explanation for this discrepancy, however, the authors 
suggested that either the subunits were not completely disassociated or there were errors 
in the peptide mapping. Electrophoresis of the a-dialkylamino acid transaminase using a 
polyacrylamide gel containing sodium dodecyl sulfate gave one band. The amino acid 
composition was determined though analysis with a Beckman 120C amino acid analyzer.
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In 1971 Sato, Honma, and Shimomura found that the molecular weight of the AIB 
decomposing enzyme, isolated from Pseudomonas sp., was 180,000 Da and that it 
contained four subunits with an individual molecular weight of 45,000 Da.(9) The 
molecular weight of the AIB decomposing enzyme, 180,000 Da, was determined by the 
Hedrick-Smith method of estimation of molecular weights by disc gel 
electrophoresis.(7 9) The AIB decomposing enzyme was analyzed via 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and a single band at 
45,000 Da was found. These results suggested that the AIB decomposing enzyme was a 
tetramer. The authors also found that analysis by spectrophotometrical titration of the 
apoenzyme, a protein without its cofactor, at two different concentrations gave an 
average of four moles of PLP bound per mole of enzyme. This also supports the 
suggestion that the AIB decomposing enzyme is a tetramer. After analysis of the 
molecular weight, an inactivation of the AIB decomposing enzyme with phenylglyoxal 
which reacts with the active site lysine was performed. The phenylglyoxal inactivated 
the apoenzyme completely; however, the holoenzyme -defined as an enzyme plus its 
cofactor- was only partially inactivated under the same conditions. Thus, the AIB 
decomposing enzyme was protected by its cofactor, PLP. It was also found that PLP 
cannot bind to the phenylglyoxal-inactivated enzyme. The decomposing and 
transaminating activities were both reduced in parallel with the decrease in PLP binding. 
These results suggest that the inactivation was caused by the PLP being unable to bind 
the active site. Also, these results support the idea that there is a single active site for 
both activities.
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91.5 DGD -  Gene Sequence
In 1990, the cloning and sequencing of Pseudomonas cepacia DNA containing the 
DGD gene was reported by Keller et al.(7) A 4.0-kbp Pstl-Pstl fragment of the 
Pseudomonas cepacia DNA containing the DGD gene was isolated. First, a Pstl 
restriction digest was performed on the Pseudomonas cepacia DNA containing the DGD 
gene. Then, the fragments were ligated into a plasmid and used to transform E. coli. 
Eventually, the E. coli was plated onto agar-2-methylalanine-glucose plates to select for 
the clone containing the decarboxylase gene. Only E. coli clones containing the DGD 
gene would be able to metabolize 2-methylalanine. After the colonies were grown, a 
4.0-kbp fragment was isolated and transferred into pUC19 giving rise to pUC19C7. Also 
a slightly smaller Xba\-EcoRl fragment was ligated into pGEM-7Zf(+) which gave rise to 
pGEM-7Z14. The vector lac promoter is upstream from the DGD gene and the lac 
promoter points towards the DGD gene. Both of these E. coli strains containing 
pUC19C7 or pGEM-7Z14 grew on 2-methylalanine suggesting that they both contained 
the functional DGD gene. The + strand of the insert was sequenced from the 
complementary pGEM-7Z sequences on the left side of the insert, and the - strand of the 
insert was sequenced from the complementary pUC19 sequences on the right side of the 
insert. A 3969-nucleotide sequence was determined. The 3’ end of the + strand 
contained the decarboxylase gene and the 3’ end of the -  strand contained the control 
gene.
The decarboxylase was purified from E. coli JM109 cells containing the plasmid 
pGEM7Z14/8b, a plasmid containing a truncated derivative of pGEM7Z14.(7) The 
purification of DGD was done in three steps i) ammonium sulfate precipitation ii) 
ion-exchange chromatography and iii) FPLC ion-exchange chromatography. DGD was 
then sequenced at the amino terminus by automated Edman degradation. The amino acid 
sequence, as encoded by the gene, is as follows:
MSLNDDATFWRNARQHLVRYGGTFEPMIIERAKGSFVYDADGRAILDFTSGQMSAVLGHCHPEIV
SVIGEYAGKLDHLFSGMLSRPVVDLATRLANITPPGLDRALLLSTGAESNEAAIRMAKLVTGKYEI
VGFAQSWHGMTGAAASATYSAGRKGVGPAAVGSFAIPAPFTYRPRFERNGAYDYLAELDYAFDL
i d r q s s g n l a a f ia e p il s s g g iie l p d g y m a a l k r k c e a r g m l l il d e a q t g v g r j g j m f a c q r d  
G VTPD1LTLSKTLG AGLPLAAIVTS AAIEERAHELG YLFYTTH V SDPLPA AV GLRVLDVV QRDGLV 
ARANVMGDRLRRGLLDLMERFDCIGDVRGRGLLLGVEIVKDRRTKEPADGLGAKITRECMNLGL 
SMNIVQLPGMGGVFRIAPPLTVSEDEIDLGLSLLGQAIERA
The active site peptides are indicated above by the underline. The peptide 
DGVTPDILTLSK contains the lysine that is thought to bind PLP, lysine 272 (K272)
Next, the active site peptide was sequenced.(7) The active site lysine-PLP imine 
bond was reduced with 3H sodium borohydride. Then, a tryptic digestion was performed 
and the peptides were separated by reversed phase high performance liquid 
chromatography (RP-HPLC). The major radioactive peptide was sequenced and all of 
the peptides matched the wildtype sequence except for K272. Therefore it was concluded 
that K272 contained the radioactive lysine.
An ATG initiation codon of the 1302-bp DGD structural gene, located at position 
1395 of the + strand, was determined to be the start of the only large reading frame that is 
required for decarboxylase activity. Also, a CCGGAG sequence was found prior to the 
structural gene. This sequence is similar to the ribosome binding sites of other bacterial 
genes. The codons used within the decarboxylase coding region are biased towards
10
codons with G or C in the third position. The amino acid composition was very similar to 
the amino acid composition determined in 1971 by Lamartiniere et al.(S)
Keller et al. stated that the control of the decarboxylase gene is most likely controlled 
by an upstream repressor.(7) To determine the location of the repressor, a series of 
experiments were carried out. Four E. coli strains, all derivations of pGEM-7Z14 with 
different small amounts of DNA excised from the end of the insert, all showed a 
repression of decarboxylase activity in the absence of 2-methlyalanine. When
2-methylalanine was provided, all of the plasmids began to express the decarboxylase 
activity again. Thus, the repressor gene is intact in these four plasmids. However, when 
the plasmid is truncated by an additional 211-bp (658-bp total) there is loss of control of 
decarboxylase expression. This deletion removes ten codons from the 3’ end of the 
repressor region; this deletion may or may not delete the entire repressor encoding region. 
In addition to the above studies, Keller et al. performed other experiments that removed 
1314-bp and 1332-bp. This removed some or all of the DNA binding domain. Hence, 
the remaining plasmid contained a promoter just prior to the decarboxylase gene. This 
would give RNA polymerase unrestricted access to the DGD promoter thus resulting in 
constant expression. Expression levels were the same as the 2-methylalanine induced 
levels that were found with the larger plasmids. These results suggest that the DGD 
promoter is within 75 nucleotides of the structural decarboxylase gene.
In conclusion, Keller et al. found the sequence for the DGD gene, they showed that 
the imine bond that PLP forms with the enzyme is via K272, which is in the active site of 
the enzyme. In addition, they determined the location of the reading frame for the
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decarboxylase gene and the repressor gene. Also, an approximate location for the DGD 
promoter was determined. Now that the DGD gene has been cloned, DGD can be 
produced more efficiently at large quantities for further experimentation.
1.6 The Crystal Structure of DGD
Toney et al. described the monomeric crystallography of DGD.(7/) Each monomer 
contains three major portions: i) a large PLP binding domain, and two smaller domains, 
ii) a C-terminal domain, and iii) an N-terminal segment (Figure 1.3a and b). The 
N-terminal segment contains a helix and a three-stranded, antiparallel P-sheet The large 
PLP binding domain contains seven p-sheets (a, g, f, e, d, b, c), six of which are parallel 
(Figure 1.3a). This p-sheet cluster is encased by eight a-helices which creates the active 
site structure. The PLP binding site has been shown to be close to the N-terminus of 
helix 4 and the C-terminus of strands e and f. The C-terminal domain is characterized by 
four stranded, antiparallel p-sheet (D, E, F, G), and three a-helices.
The two monomers are tightly associated to form a dimer. Dimerization results in 
burying of a large solvent accessible surface area, which stabilizes the interaction of both 
monomers. In fact, the active sites become close enough to each other causing the PLP 
phosphate atoms to be separated by only 15 A and enabling the sharing of residues from 
both monomers in the active site domains. This sharing of residues further stabilizes the 
binding of this critical cofactor, PLP, in the active sites. The dimeric structure is further 
stabilized at the interface by the formation of a well ordered cluster of charged residues 
created by helices and loops within the N-termini of both monomers. Helix 2 of each
13
subunit packs together and forms a hydrophobic region. Thus, the active site consists of 
amino acids from both monomers which come together to form a well ordered and stable 
active site. Hydrogen bond interactions between the C-terminus of one strand and the 
N-terminal P-sheet of an adjacent strand provide a clamp that facilitates one of the closest 
interactions of both large domains and a small domain of one monomer.
N-terminal Segment C-terminal Domain
PLP Binding Domain
Rectangles=Helices
Arrows=P-sheet
Figure 1.3a -  Two dimensional representation of the helices and p-sheets in DGD. Helix 2 is involved 
in the dimeric interface of DGD. The N-terminal of Helix 4 is near the PLP binding site. Helix 6 is 
involved in the tetrameric interface. Note: This figure is a reproduction of the original drawing 
from Toney et al.
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Figure 1.3b -  Three dimensional representation of the helices and p-sheets in DGD. Note: This figure 
was produced by Dr. John Keller, University of Alaska Fairbanks. Protein data bank file 1D7U.
Dgd subunit with l-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,0- 
cycloserylamide bound at the active site. Image created with Rasmol v. 2.6.
DGD is a dimer of dimers and exists as a tetramer. The tetrameric interface is three 
times smaller than the dimeric interface, and it is formed by interactions between helix 6 
and its N-terminal associated loop with their symmetrical mates in adjacent strands. 
About ten residues from each subunit participate in the formation of the tetramer.
DGD has two alkali metal binding domains, a predominantly potassium binding site 
near the active site and a sodium site associated with the surface. The close proximity of 
site one to the active domain has been proposed to account for the dependence of DGD 
function on potassium. The importance of this interaction is further indicated by 
structural disruption when sodium is bound to this site which inhibits enzyme activity as 
determined by Lamartiniere et al. in 1971. Like other PLP binding enzymes such as 
tryptophanase and tyrosine phenol lyase, cations also play an important role in the 
regulation of DGD enzyme activity. However, ion dependence is not absolute because 
high concentrations of PLP can restore DGD activity in the absence of cations 
(Hohenester et al., 1994). (72)
In the DGD crystal structure, the potassium ion is liganded by interactions with five 
amino acids (Asp307, Leu78, Thr303, Val305, and Ser80) and a water molecule 
contributing hydrogen bonds and other electrostatic interactions. The sodium ion 
coordination interactions are contributed by the carboxylate group of Asp307 and the 
carbonyl atoms of Leu78 and Val305. Differences in the interaction with water 
molecules contribute to the different geometries existing between the potassium and the 
sodium binding sites. The exchange of ions, particularly at the potassium site, will affect 
the conformation of the active site reside Tyr301 and other distal regions.
Enzyme activity is dependant on the following critical amino acids and the generation 
of reactive intermediates. (/) The pyridine nitrogen of the PLP forms a strong hydrogen 
bond / salt bridge with Asp243 which hydrogen bonds to Hisl39 and Asnl 13. This 
interaction enables the chemical change of PLP into an aldimine via Lys272. (h) It is
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proposed that decarboxylation of L-isovaline with the carboxylate group of L-isovaline 
perpendicular to the PLP ring plane is important for catalysis . The methyl group would 
point up towards Tyr301 and Metl41; the ethyl group of L-isovaline would then lie 
against the Trpl38 indole ring. The transamination of L-isovaline would put the C“-H 
bond perpendicular to the PLP ring plane and on the same side as Lys272. The Lys272 
would act as a general base catalyst in analogy to the aspartate aminotransferase.
(Hi) Crystallography indicates that the active site is unique in having three subsites that 
contribute to catalysis.(73) Subsites A and B accommodate carboxylate groups and are 
thought to be active in decarboxylation. In contrast, subsite C is proposed to facilitate 
transamination to L-amino acids (Figure 1.1).
In conclusion, Toney et al. found that DGD has two alkali metal binding domains that 
regulate enzyme activity and explain the inhibitory effects of sodium on DGD. A 
detailed description of a monomer and the tetramer as a whole was presented based upon 
crystal structures of DGD, and lead to a proposed mechanism for DGD transamination 
and decarboxylation in the same active site.
1.7 DGD — a Decarboxylating Transaminase or a Transaminating Decarboxylase?
Since the DGD catalyzes amino transfer and decarboxylation, many have wondered if 
DGD was first an aminotransferase that gained the ability through evolution to 
decarboxylate, or vice versa. In 1990, Keller et al. found that the DGD amino acid 
sequence deduced from the dgd gene was homologous with the amino acid sequence 
found for mammalian ornithine aminotransferase.(7) It was also determined that the
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active site of DGD was similar to that of other aminotransferases. At the optimum 
alignment of the DGD and the rat ornithine aminotransferase, only one pair of lysines 
align. These lysines are K272 of the DGD sequence and K292 of the rat ornithine 
aminotransferase. It was shown in 1986 by Simmaco et al,. that K292 is in the active site 
of ornithine aminotransferase.(77) In 1990 Keller et al. showed that K272 was in the 
active site of DGD. Keller et al. also reported that the amino acid sequences on both 
sides of these lysine residues are conserved in several aminotransferases. In addition to 
the comparison of these two enzymes, DGD was compared to several other 
decarboxylases through several database searches, and no significant similarities were 
found between DGD and other decarboxylating enzymes. Keller et al. also noted that 
there was no active site histidine-lysine pair in DGD which is found in all known 
prokaryotic PLP dependent decarboxylases. In 1991, it was found that the polyalanine 
model of DGD showed a fold similar to aspartate aminotransferase and pyruvate 
aminotransferase.(7 J) In addition, in 1995 Toney et al. performed an overlay of the DGD 
structure with the structure of aspartate aminotransferase after the crystal structure of 
DGD was found.(7/) For the large domain of DGD, all seven of the pleated sheet strands 
are closely related, and four out of nine of the DGD helices show overlap with aspartate 
aminotransferase. Also, all three of DGD’s helices in the small domain are very similar 
to the small domain of aspartate aminotransferase. In addition, the active sites of the two 
molecules are very close in structure with exactly the same positions, as stated by Toney 
et al., of the PLP pyridine nitrogen atom, the aspartate carboxylate group that is its 
hydrogen bond-salt partner, and the imidaxole nitrogen atom that hydrogen bonds to this
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carboxylate group. This information strongly implies that DGD is more than likely a 
“decarboxylating aminotransferase” and not a "transaminating decarboxylase”.
Part II -  Fluorinated Amino Acids 
1.8 Fluorinated Amino Acids as Enzyme Inhibitors
The use of fluorinated amino acids can give important clues to the mechanism of an 
enzyme with the parent substrate. Substituting fluorine in place of hydrogen in an amino 
acid that is a substrate for an enzyme can cause mechanism-based inactivation of the 
enzyme. Since fluorine does not cause any significant steric changes in the enzyme, 
important reactions of the enzyme can be evaluated based on the mechanism of the 
fluorinated inhibitor. Fluorinated analogues of amino acids are useful because they can 
stop the reaction of an enzyme just prior to the release of the substrate. Analysis of this 
complex can give rise to several mechanistic clues that can be extrapolated back to the 
normal reaction. The following descriptions give several examples in which fluorinated 
amino acids were used to gain information on the enzyme’s reaction with the normal 
substrate.
1.9 Fluorinated Amino Acids and Decarboxylases
In 1970, Unkeless and Goldman found that y-aminobutyric acid metabolism in the 
nervous system can be inhibited by use of the fluorinated analogue of glutamate.(75) 
Glutamate decarboxylase reacts with L-y-glutamate to from y-aminobutyric acid
(GABA), and the fluorinated analogue of L-y-glutamate reacts with glutamate 
decarboxylase to form a-fluoro-y-aminobutyric acid (F-GABA). It was found that the L 
isomer of the fluorinated glutamate had a higher affinity for the enzyme than the D 
isomer. This was no surprise since the L isomer of glutamate is the normal substrate for 
glutamate decarboxylase. The Km was determined to be 5 x 10'3 M which is the same as 
that for L-glutamate. Also, F-GABA can inhibit GAB A uptake. These findings provide a 
beginning to the use of these compounds in determining the use of GABA in the brain.
In 1979, Sato et al. found that P-chloro-L-alanine inactivates a-aminoisobutyrate 
decomposing enzyme. (16)P-chloro-L-alanine is a substrate for the AIB decomposing 
enzyme when an a-ketoacid is absent. Equimolar production of chloride, ammonia and 
a-ketoacid were observed. The production of chloride suggested that the ketoacid 
produced was pyruvate and not chloropyruvate which would be the product if 
transamination had occurred. The production of pyruvate was confirmed by spectral 
analysis. Thus, it is likely that a,P-elimination is the mechanism of this reaction. Sato et 
al. also concluded that the D-form of P-chloro-L-alanine is not a substrate for the AIB 
decomposing enzyme. Since it was found that the reaction does not occur in the absence 
of PLP, this a,P-elimination is PLP dependent. The AIB decomposing enzyme has a 
higher affinity for P-chloro-L-alanine than for AIB or alanine. A time course of the 
formation of pyruvate from the inactivation of the AIB decomposing enzyme with 
P-chloro-L-alanine showed a small deviation from a straight line. Also, the relationship 
between the loss of activity and a,P-elimination was linear. It was reported that AIB 
decomposing activity, transamination, and a,P-elimination were all three lost in parallel.
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From these results, Sato et al. concluded that one of the intermediates of a,P-elimination 
was responsible for the inactivation of the AIB decomposing enzyme, and an identical 
active site was utilized for each of the three reactions of the AIB decomposing enzyme.
In 1986, Hayashi et al. found that (S)-a-fluoromethylhistidine was an inhibitor of 
Morganella morganii AM-15 histidine decarboxylase.(77) Histidine decarboxylase is a 
PLP dependent enzyme, and the holoenzyme was inactivated by 
(S)-a-fluoromethylhistidine, but the apoenzyme was not inhibited by 
(S)-a-fluoromethylhistidine. It was found that a single molecule of 
(S)-a-fluoromethylhistidine inhibits one enzyme subunit under optimal conditions. The 
kmactof the reaction was found to be 32.2 min'1. Also, it was determined that L-histidine, 
the normal substrate, protects the enzyme against inactivation. These results indicate that 
(S)-a-fluoromethylhistidine is a mechanism-based inhibitor of histidine decarboxylase. 
Once the inhibitor is bound to the enzyme, it can be removed by the addition of heat or 
urea. The released product was not characterized. However, they did find that the 
released product contained a tritium label if the inhibitor was tritiated, 
a-fluoromethyl-[ H] histidine. Hayashi et al. proceeded to react a-fluoromethyl-[ H] 
histidine with enzyme reduced by sodium borohydride and carboxymethylated. After the 
reaction was complete, the complex was trypsinized and the peptides were separated by 
RP-HPLC. Only one peak contained radioactivity, referred to as T-lOm, and it contained 
85% of the original amount of tritium added to the reaction. This indicated that there was 
only one modification made to the enzyme by the inhibitor. A ratio of one inhibitor: one 
peptide: one PLP was found. A native histidine decarboxylase was carboxymethylated
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and digested with trypsin and subjected to RP-HPLC for comparison. The peptide maps 
of both the carboxymethylated enzyme and inhibited enzyme were essentially the same. 
The carboxymethylated enzyme had a peak very similar to the radioactive peak in the 
inhibited enzyme peptide map, referred to as T-10. That peak was collected and purified 
for analysis. Upon sequencing of T-10 and T-lOm, it appeared that they contained the 
same amino acid sequence except for one amino acid, serine was in the second position in 
T-10 and the second position in T-lOm was unidentifiable. However, the second position 
of T-10m did contain radioactivity. Thus, it was concluded that serine is the modified 
amino acid in the inhibited histidine decarboxylase.
In 1995 Reguera et al. produced fluorinated analogues of L-omithine that inhibit 
ornithine decarboxylase.(7S) One irreversible inhibitor of ornithine decarboxylase is 
a-difluoromethylomithine (DFMO). DFMO was utilized as a clinical agent for the 
treatment of trypanosomiasis (sleeping sickness). Trypanosomiasis is an infectious 
parasitic disease carried by tsetse flies and characterized by inflammation of the brain and 
the covering of the brain (meninges). This paper demonstrates the relevance of the use of 
fluorinated inhibitors in human disease treatments.
1.10 Fluorinated Amino Acids and Transaminases
In 1975, Relimpio et al. found that a-trifluoromethyl-DL-alanine is an inhibitor of 
aspartate transaminase, a PLP dependent enzyme. (7 9) The inhibitor, 
a-trifluoromethyl-DL-alanine, was produced in the form of a fluorinated amino acid-PLP 
complex. The complex was reacted with the enzyme at room temperature. The complex
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completely inactivated the enzyme. When the racemic inhibitor was used, only one half 
of the amount of inhibitor was used by the enzyme suggesting that only one isomer is 
able to bind to the active site of aspartate transaminase. It was found that the fluorinated 
inhibitor could not be displaced by the cofactor or any amino acid combinations 
suggesting that there is a high affinity between the inhibitor and enzyme. The inhibitor 
was not released upon dialysis or column chromatography (Sephadex G-25). However, 
the a-trifluoromethyl-alanine can be displaced by treatment with potassium phosphate 
buffer, pH 6.0. This treatment can completely restore catalytic activity. Since the bond 
between the enzyme and inhibitor complex is easily reversible, it is safely concluded that 
this is not a covalent bond.
In 1981, Wang et al. found that D-fluoroalanine is a mechanism-based inhibitor of 
serine transhydroxymethylase, a PLP dependent enzyme.(26) Serine 
transhydroxymethylase can catalyze the slow transamination of D-amino acids, namely 
D-alanine, to form pyruvate, PMP, and apoenzyme. The fluorinated analogue of 
D-alanine, D-fluoroalanine, acts as a suicide substrate for serine transhydroxymethylase. 
Wang et al. found that D-fluoroalanine inhibits serine transhydroxymethylase purified 
from rabbit and lamb liver in the presence of tetrahydrofolate. The Km of D-fluoroalanine 
is high at 50 mM, the same as that of D-alanine, which suggests that this fluorinated 
amino acid would not be useful for in vivo studies of inactivation of liver cell serine 
transhydroxymethylase because the inhibitor would not have a higher affinity for the 
enzyme than the natural substrate. Although D-fluoroalanine would not make a clinically
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useful mechanism-based inhibitor, it does have utility as an antibacterial agent since it 
can inactivate alanine racemases.
In 1996, Kato et al. found that S-(l,l,2,2-Tetrafluoroethyl)-L-Cysteine is an inhibitor 
of aspartate aminotransferase and alanine aminotransferase.(27) 
S-(l,l,2,2-Tetrafluoroethyl)-L-Cysteine (TFEC) is a xenobiotic which may result in an 
increased risk for some cancers. Kato et al. hypothesized that the reason for the toxicity 
of TFEC is due to inhibition of important PLP dependent enzymes such as aspartate 
aminotransferase and alanine aminotransferase. After performing several experiments, 
they found that TFEC inactivates aspartate aminotransferase in purified pig heart, rat 
brain, and rat kidney. These inactivations are enhanced in the presence of 
a-ketoglutarate, and very little pyruvate is detected. These results suggest that the 
reaction of the PLP-TFEC complex to PMP and the keto form of the TFEC, 
transamination, competes favorably with the conversion to PLP and pyruvate. Also, 
TFEC inactivates alanine aminotransferase in purified pig heart in a time dependent 
fashion, and L-glutamate protects this activation. Kato et al. showed that PLP dependent 
enzymes, aspartate aminotransferase and alanine aminotransferase, are indeed inhibited 
by TFEC which may cause an increases in certain types of cancer. These findings justify 
further investigation of TFEC as a carcinogen.
1.11 A Mechanism-Based Inhibitor of DGD
In 1979, Keller and O’Leary found an irreversible mechanism-based inhibitor of the 
Pseudomonas cepacia a-dialkylamino acid transaminase, known today as DGD.(2) As
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stated previously, the normal substrate for DGD is 2-aminoisobutyrate (AIB), also known 
as 2-methylalanine. The enzyme is a PLP dependent decarboxylating aminotransferase. 
Decarboxylation of AIB results in the formation of carbon dioxide, acetone, and the 
amino form of the cofactor (PMP). Then, transamination of the pyruvate forms L-alanine 
and regenerates the cofactor in the PLP form. Keller and O’Leary found that 
(+)-3,3,3-trifluoro-2-aminoisobutyrate (F3AIB) inhibits DGD in a time dependent 
fashion in the presence of PLP. The reaction with the inhibitor decarboxylates the 
substrate, and then covalently binds to the active site of DGD, completely inactivating the 
enzyme. The apoenzyme is not inactivated by F3AIB. The first order rate constant was 
found to increase with increasing concentrations of F3AIB. Upon dialysis of the 
inhibited enzyme the activity could be not restored even after several hours which 
suggest a covalent attachment of the inhibitor to the enzyme. The product of the natural 
reaction, L-alanine, is a known competitive inhibitor with the natural substrate, AIB. 
L-alanine is also a competitive inhibitor of F3AIB. In addition, there is also some 
protection of the enzyme provided by AIB.
Keller and O’Leary performed experiments with [1-14C] F3AIB so that the molar 
ratio of inhibitor decarboxylated to enzyme monomer inactivated could be determined.(5) 
Upon liberation of [14C] CO2 from a known amount of enzyme, the labeled CO2 was 
trapped and quantified. A value of 10 was determined for the ratio of decarboxylated 
inhibitor to enzyme monomer inactivated.
Keller and O’Leary proposed that the enzyme is inactivated at the active site based on 
their observations that AIB and L-alanine protect the enzyme from inactivation and that
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the inhibitor is decarboxylated with a ratio of 10 moles of CO2 to each monomer 
inactivated. In addition, they also suggested that the inhibitor covalently attaches to the 
enzyme. Thus, F3AIB is a mechanism-based suicide inhibitor of DGD.
1.12 R Isomer of F3AIB, a Better Suicide Inhibitor of DGD than the S Isomer
In 1982, Keller found that the (+)-isomer of F3AIB is more active against the 
enzyme, dialkylamino acid transaminase than the (-)-isomer of F3 AIB.(22) The 
(-)-isomer has been found to inactivate the enzyme slowly or not at all. When the 
enzyme is reacted with racemic F3 AIB the (-)-isomer can get into the active site of the 
enzyme and inhibit the (+)-isomer from inactivating the enzyme thus the (-)-isomer is a 
competitive inhibitor. After the (-)-isomer disassociates from the enzyme, the (+)-isomer 
can move into the active site and completely inactivate the enzyme.
In 1984, Keller and Day found that the (+)-isomer of F3AIB corresponded to the R 
configuration of F3AIB (Figure 1.4).(22) Through analysis of the crystals by X-ray 
diffraction studies of (R)-N-chloroacetyl-(+)-3,3,3-trifluoro-2-aminoisobutyric acid, 
Keller and Day were able to show that D-alanine and
(R)-N-chloroacetyl-(+)-3,3,3-trifluoro-2-aminoisobutyric acid both have the same 
configuration of methyl, amino acid, and carboxylate groups. These findings support the 
previous conclusions of Bailey et al. that the D- and L-alanine are both substrates for 
dialkylamino acid transaminase; however, they produce different results when processed 
by the enzyme. D-alanine is decarboxylated and transaminated to acetaldehyde while 
L-alanine is transaminated to pyruvate. These findings also support the finding by Keller
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et al. that inactivation of the transaminase by F3AIB is accompanied by decarboxylation. 
From this evidence, Keller et al. concluded that F3AIB and the normal substrate have 
similar binding patterns DGD thus F3AIB can be referred to as a mechanism-based 
suicide inhibitor of DGD.
R-2-trifluoromethylaIanine S-2-trifluoromethylalanine
Figure 1.4 -  Isomers of F3AIB showing the R and the S configuration.
Part III -  Mass Spectroscopy
1.13 Mass Spectroscopy of Modified Proteins
Mass spectroscopy is an extremely useful tool in analyzing peptide mixtures that are a 
result of enzyme digestions.(2i) The reason that LC/MS (Liquid Chromatography/Mass 
Spectroscopy) has become such a powerful tool is because the HPLC portion of the 
instrument separates the sample and the mass spectrometer can immediately analyze the 
samples at femtomole levels. LC/MS can be used to confirm the sequence of proteins, 
and it can be used to determine the location of a change in an amino acid sequence.
Davis et al. reported several examples of the utility of LC/MS. One example is the use of
CF.
NH3+ nh3+
trypsin and LC/MS/MS to analyze a human hemoglobin variant. From this analysis, 
Davis et al. found that one of the peptides in this protein had a substitution of Lys for 
Gin. This substitution had been previously known; however, Davis et al. fully 
characterized the variant and confirmed the substitution with a single LC/MS/MS run.
Also, instead of comparing peptide maps and analyzing retention times the MS/MS 
will analyze each peak and determine the mass. Thus, one can determine if a HPLC peak 
is at a different retentions time due to run-to-run variations or if there is indeed a different 
peptide in the sample, such as a peptide with a covalently bound inhibitor that caused the 
retention time to shift(24)
In 2001, Chen and Frey found the presence of an aldimine linkage between PLP and a 
lysine residue in the active site of lysine 2, 3-aminomutase (LAM).(25) LAM catalyzes 
the interconversion of L-lysine and L-p-lysine. LAM is a PLP dependent enzyme 
although the mechanism by which it utilizes PLP is very different than the typical PLP 
dependent enzymes. PLP dependent enzymes usually involve the PLP binding to the 
active site by forming an aldimine link between the carbonyl group of the cofactor and 
the e-amino group of the active site lysine. The amino group of the substrate replaces the 
e-amino group of the active site lysine and the reaction proceeds via stabilization of 
amino acid carbanions. The LAM reaction is unique because it utilizes a radical 
rearrangement mechanism. The common PLP binding motif S-X-X-K (PLP) was found 
in LAM. Also, the amino acids flanking this motif were found to be similar to the PLP 
binding sites of aspartate aminotransferases. Spectral changes upon reduction with 
sodium borohydride suggested that there was an aldimine linkage. To determine if an
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active site lysine was involved in this aldimine linkage, NaBPL reduced LAM and 
nonreduced LAM were carboxymethylated, denatured, digested with trypsin, and then 
analyzed by HPLC with a C l8 column. Upon spectral analysis, the peptides from the 
reduced enzyme showed an absorption band at 280 nm and 325 nm, but the non reduced 
enzyme showed no absorption band at 325 nm. This indicates that there was a loss of 
PLP in the non reduced enzyme. The chromatograms from the HPLC were compared; 
the chromatograms were the same except for the NaBH4 reduced LAM showed a peak at
23.7 m whereas the nonreduced enzyme had no peak at this retention time. This peak 
was subjected to analysis by ESI/MS. The molecular mass of this peptide was found to 
be 3860.64 ± 0.26 Da. This is equal to the mass of a 36 residue peptide of LAM 
(3629.05 Da) plus 231.14 mass units for the attachment of PLP. The peptides from the 
nonreduced and the reduced LAM were then analyzed with LC/MS. A peptide with a 
mass of 3859.98 ± 0.18 Da was found in the reduced enzyme, but it was not found in the 
nonreduced enzyme. However, two peptides with masses of 1974.36 ± 0.41 Da (residues 
326-346) and 1672.22 ± 0.30 Da (residues 347-361) were identified in the nonreduced 
enzyme; however, they were absent in the LC/MS of the reduced enzyme. These two 
peptides are two halves of the larger peptide found in the reduced enzyme which suggests 
that Lys 346 is covalently modified by PLP thus making it unrecognizable as a trypsin 
cutting site which results in two peptides remaining together. In addition, the peptides 
were sequenced by MS/MS which also confirmed a 231 mass attachment to Lys 346. 
These experiments demonstrate that ESI/MS, LC/MS, and MS/MS can distinguish 
between a nonmodified peptide and a modified peptide.
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In 2001, Li et al. found a mechanism-based inactivator of S-adenosylmethionine 
decarboxylase in vivo, and through the use of MS they showed that this inactivation 
correlates with a posttranslational modification of the a  subunit of the enzyme.(2<5) 
S-adenosylmethionine decarboxylase (AdoMetDC) is required for the biosynthesis of 
spermidine and spermine. These studies were conducted using enzymes from coli, 
Saccharomyces cerevisiae, and Salmonella typhimurium. The enzyme was synthesized 
as a proenzyme which is cleaved posttranslationally to form an active enzyme. The 
mature enzyme is composed of a (3 subunit and a a  subunit. AdoMetDC contains a 
covalently bound pyruvoyl end group within a a  subunit that is required for the enzyme 
to be active. It is likely that the decarboxylation of AdoMetDC proceeds via formation of 
a Schiff base between the pyruvoyl group and the amino group of the substrate. Also, it 
is known that the product of the reaction which is decarboxylated S-adenosylmethionine 
(dcAdoMet) can inhibit the enzyme. Upon production of AdoMetDC, Li et al found that 
a large amount of the enzyme was inactive. Thus, the purified enzymes were trypsinized 
and separated via HPLC with a C3 or a C l8 column. The separated peptides were then 
analyzed by LC/MS/MS. In addition to two expected peaks each representing a subunit, 
there were one or two additional peaks at masses 57 ± 1 and 75 ± 1 Da. The unexpected 
peaks accounted for 30-70% of the a  subunit which suggested that there was extensive 
modification of the enzyme in vivo. Li et al. also found that the pyruvoyl groups of the a  
subunit can be transaminated to alanine. This reaction is similar to that of the 
decarboxylation-dependent transamination of pyridoxal phosphate dependant enzymes. 
Upon digestion of the E. coli enzyme with trypsin and peptide mapping by LC/MS, a
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modification of Cys 140 was revealed. MS/MS studies indicated a +76 modification of 
Cys 140. Li et al. speculated that the modification was caused by the reversible binding 
of the product, dcAdoMet, which then causes an irreversible modification of the enzyme. 
Assays for dcAdoMet in trichloroacetic acid cell extracts did not show an increase in 
dcAdoMet. The loss of enzyme activity correlates with the increase in the modified 
enzyme, but the loss of activity is greater than the amount of the modification. These 
results would be expected if modification of only one or two of the four subunits 
inactivated the enzyme. Thus, Li et al. concluded that the inactivation of the enzyme 
proceeds via the occasional transamination reaction that is followed by alkylation of the 
Cys 140 sulhydryl group which completely inactivates the enzyme.
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Chapter 2 -  Materials and Methods 
Part I -  Materials
An autoclave was used to sterilize solutions. A Sorvall RC 5B Plus centrifuge with a 
Super-lite GSA rotor and a SS-34 rotor was used for centrifugation. A Hewlett Packard 
Diode Array UV spectrophotometer was used with 1 cm plastic cuvettes for protein 
concentration assays and a 0.5 cm quartz cuvette was used for kinetic assays. Petri 
dishes, toothpicks, 15 mL culture tubes, and a shaker were used to grow E. coli. A W225 
Heat Systems Ultrasonics sonicator, lA inch dialysis tubing, a Gilson peristaltic pump, 
detector, and fractionator, and a 2.5 x 12 cm column were used in the purification 
process. The Beckman HPLC contained a model 126 solvent module, a 168 detector, a 
508 Autosampler, and System Gold Version 1.7. The column utilized was an Alltech 
Econosphere C l8 5 p, 15 mm x 4.6 mm column with an Alltech 7.5 mm x 4.6 mm 
column guard, and an Ansys flow-through design back pressure regulator. Solvents were 
degassed. Also, a Labconco centravap system was used to dry HPLC fractions. Finally, 
samples were analyzed on a VG or Kratos multi-sector tandem mass spectrometer at the 
Washington Univ. Center for Biomedical and Bioorganic Mass Spectrometry.
E. coli JM109 carrying the plasmid pJKDGD-A2.2 was used to extract and purify 
DGD. Tryptone, yeast extract, NaCl, agar, ampicillin, triethanolamine, glycerol, 
monobasic and dibasic potassium phosphate, isopropyl P-D-thiogalactopyranoside 
(IPTG), tris base, 2-methylalanine, pyruvate, pyridoxal 5’-phosphate (PLP), and KC1
were utilized in media for growing E. coli and in reaction buffers. NaOH and HC1 were 
used to change the pH of solutions. Bovine Serum Albumin (BSA) and Bradford 
Reagent were used to determine protein concentrations. Ammonium sulfate was used to 
precipitate out undesired proteins. Bio Rad ready made SDS-PAGE 12% Tris-HCl with 
10 wells and a 30 pL comb and coomassie blue were used for SDS-PAGE analysis. Bio 
Rad P-6D6 resin and Supelco DEAE-650M resin was required for column 
chromatography. Sodium borohydride (Altech, Inc) was used to reduce DGD, and 
L-l-tosylamide-2-phenylethyl chloromethyl ketone (TPCK) trypsin was needed to cleave 
DGD. HPLC grade acetonitrile and formic acid were the HPLC solvents used. Finally, R 
(+) isomer of F3AIB and racemic F3AIB-d3 were used to inhibit DGD.
Part II - Methods
2.1 DGD Purification
The plasmid carrying the DGD gene was grown in E. coli so that the DGD protein 
could be extracted and purified through sonication, ammonium sulfate precipitation, 
dialysis, and ion-exchange chromatography for further studies of this enzyme.
a. Cell Growth
DGD was purified from E. coli JM109 carrying the plasmid pJKDGD-A2.2 which 
contains the DGD gene (Figure 2.1).
32
33
5986 bp
Figure 2.1 -  pJKDGD-A2.2 plasmid. This plasmid carries the DGD gene.
The purification was done in two batches. JM109 pJKDGD A2.2 was plated on Luria 
Broth (LB) consisting of sterile 1% tryptone, 0.5% yeast extract, 1% NaCl, 0.75% agar, 
and 0.1 mg/mL ampicillin in water (LB-AMP plates). The plates were incubated at 37°C 
overnight. Then, an isolated colony was removed with a sterile toothpick and placed into 
0.2 mL of sterile LB (1% tryptone, 0.5% yeast extract, 1% NaCl, and 0.08 mg/mL 
ampicillin in water). Approximately 0.028 mL of the colony in LB was placed into seven 
15 mL culture tubes containing 2.5 mL of sterile LB each. The tubes were shook at 200 
RPM at 37°C for approximately 12 h. One tube was preserved at -70°C for later use. 
Then, two tubes were placed into a Femback flask containing 900 mL of Terrific Broth
(1.2% tryptone, 2.4% yeast extract, 0.004% glycerol, 0.17 M monobasic potassium 
phosphate, 0.72 M dibasic potassium phosphate), plus 0.05 mg/mL ampicillin, and 0.5 
mM isopropyl P-D-thiogalactopyranoside (IPTG). IPTG is a synthetic inducer of the 
lactose operon. It induces the operon by vastly decreasing the affinity of the repressor for 
DNA. The inactivation of the repressor stimulates transcription because it removes the 
steric block of the repressor-inducer complex. Next, three Femback flasks were shook 
for 10 h at 37°C. The cells were grown to an OD at 600 nm of 0.86. This was 
determined by taking the UV spectrum of 0.2 mL of cells diluted with 1.5 mL of water.
b. Protein Assay
A standard curve was made by taking readings on a Hewlett Packard Diode Array UV 
spectrophotometer at 595 nm with 1 cm plastic cuvettes consisting of 0, 5, 10, 20, 30, and 
40 pg of bovine serum albumin (BSA) in 1.5 mL of Bradford Reagent. (27) The 
Bradford method utilizes a dye that binds proteins and causes a change in color which 
results in a change in absorbance. Protein absorbance versus protein concentration was 
plotted for the determination of unknown protein concentrations (Figure 2.2). The 
protein concentration of a protein can be determined by the absorbance when the 
absorbance is plotted on the graph in figure 2.2.
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Standard Curve with BSA
y =  12.978x2 + 1 .1656X -4 .3908  
R2 = 0 .9929
ug of BSA
Figure 2.2 -  Protein concentration standard curve with BSA. The absorbance of an unknown 
protein can be plotted in this graph to determine the protein concentration.
c. Ammonium Sulfate Precipitation and Dialysis
Next, the cells were centrifuged in a Sorvall RC 5B Plus centrifuge with a Super-lite 
GSA rotor which was precooled to 4°C, unless otherwise noted, at 6,000 RPM for 10 
min. The supernatant was discarded; the resulting cell pellet weighed 23.5 g. The 
sonication buffer consisted of 30 mM Tris, 50 mM KC1, 50 mM NaCl, 1 M ammonium 
sulfate, 1.5 mM 2-methylalanine, 2.7 mM pyruvate, and 20 pM PLP at pH 7.9. The cells 
were resuspended in 150 mL of sonication buffer, and stirred on ice until the mixture was 
at 4°C. The cells were sonicated six times in 5 min intervals with a W225 Heat Systems 
Ultrasonics sonicator. They were allowed to cool to slightly below 4°C in between 
sonication periods, and they were never allowed to exceed 7°C throughout the sonication 
process. The absorbance of the cells was taken at 595 nm after each sonication period
from the 2nd to the 6th by removing 5 pL and placing it into 1.5 mL of Bradford Reagent 
and reading the absorbance (Table 3.1) (27). After the cells were sonicated, they were 
spun at 12,000 RPM for 20 min. After centrifugation, 4 pL of the supernatant was 
removed and placed into 1.5 mL of Bradford Reagent, and the absorbance was taken at 
595 nm (Table 3.1). The supernatant was poured off and 113 mL of a 3.8 M ammonium 
sulfate solution was added to precipitate out undesired proteins. The solution was 
magnetically stirred on ice, and then centrifuged at 10,000 RPM for 20 min. The 
supernatant was poured off, and the pellet was resuspended in 100 mL of dialysis buffer 
on ice. The dialysis buffer consisted of 20 mM triethanolamine, 5 mM KC1, 5 mM NaCl, 
2 mM pyruvate, 1 mM 2-methylalanine, and 18 pM PLP at pH 7.9. The pellet was not 
shaken or stirred, but it was allowed to dissolve slowly on ice. When the pellet was 
completely dissolved, 4 pL were assayed for protein concentration by the Bradford 
method. The dissolved pellet was placed in 1 14 inch dialysis tubing that had been 
soaking in deionized water for 1 h. The tubing was clamped shut and placed in a 2 L 
graduated cylinder with approximately 1.9 L of dialysis buffer and a 1.5 inch magnetic 
stir bar. The tubing was stirred at 4°C overnight. The following day, the contents of the 
dialysis tubing was centrifuged at 12,000 RPM for 20 m at 4°C.
d. Ion-Exchange Chromatography
A Gilson peristaltic pump, detector, and fractionator were used. The Supelco 
DEAE-650M resin, 75 mL, was added to 250 mL of water and packed into a 2.5 x 12 cm 
column. Approximately, 125 mL of a 5 mM NaCl and 5 mM KC1 buffer was run through 
the column prior to adding the sample. Then, the sample was loaded and followed by a
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gradient of a low (5 mM) to a high (250 mM) KC1 and NaCl concentration. The detector 
was set to read at 290 nm, and the sample was pumped through the column at a rate of 2 
mL/min. Then, 4 mL fractions were collected. Fractions were analyzed by placing either 
3, 4, or 10 pL into 1.5 mL of Bradford Reagent and taking the absorbance at 595 nm.
The protein concentration was calculated and plotted using the absorbance data and the 
equation of the line from the standard curve (Figure 3.1a). Also, a SDS-PAGE was 
performed via the Bio Rad protocol with a Bio Rad ready made 12% Tris-HCl gel with 
10 wells and a 30 pL comb (Figure 3.1b). The only exception to the Bio Rad protocol 
was that the concentration of the Coomassie Blue staining solution was reduced to 0.05% 
to reduce blue background in the gel.
e. Activating Column
Finally, an activating column was run to load the DGD with the cofactor, PLP.
The column consisted of 3 g of Bio Rad P-6D6 resin in 50 mL of 50 mM potassium 
phosphate buffer pH 7.9 with 2 mM pyruvate, 1 mM 2-methylalanine, and 50 pM PLP. 
The slurry was allowed to hydrate for 30 m at room temperature. Then, a 1.5 x 12.5 cm 
column was packed with the resin. The column was equilibrated with potassium 
phosphate buffer. The detector was set to 290 nm, and the sample was pumped through 
the column at a rate of 1 mL/min. The sample was eluted in 50 mM potassium phosphate 
buffer pH 7.9 with 2 mM pyruvate, 1 mM 2-methylalanine, and 50 pM PLP in 3 mL 
fractions. The fractions were analyzed spectrophotometrically at 595 nm in 1.5 mL of 
Bradford Reagent.
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The protein was assayed for the uptake of the substrate, 2-methylalanine. First, a 
scan of the enzyme alone is taken, then the enzyme is reacted with the substrate and 
another scan is taken. The scan should show the change of PLP into PMP. This was 
done by taking a scan of 100 mM dibasic potassium phosphate pH 7.0 and 100 pL of 
purified DGD. The total volume of the enzyme substrate reaction was 0.5 mL. Next, 100 
mM 2-methylalanine was added and the mixture was scanned again (Figure 3.2).
Finally, fractions 18-23 from the column were combined and concentrated using 
Centricon-30 Concentrators in 50 mL centrifuge tubes. Before and after the 
concentration of the enzyme, the protein concentration was determined via the Bradford 
method described above (Table 3.2). The pooled fractions had a pale yellow color due to 
the presence of DGD. The Sorvall RC 5B Plus centrifuge with a SS-34 rotor was spun at
5,000 RPM for 20 min three times. The rotor was precooled to 4°C. After the fractions 
were combined, a kinetic assay was run on the purified DGD (Figure 3.3). This assay 
observes the loss of pyruvate as it is consumed by the enzyme. Thus, as the pyruvate is 
lost the absorbance decreases. To perform this assay a reaction buffer was prepared 
which consisted of 50 mM dibasic potassium phosphate pH 7.0, 2 mM pyruvate, 20 mM 
2-methylalanine, and 10 pM PLP. The purified DGD, 5 pL, was added to 1 mL of the 
reaction buffer and time points were taken every 2 s at 222 nm in a 0.5 cm cell. The 
assay ran for 180 s. Finally, the protein was stored at -70 °C in 0.5 mL aliquots.
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2.2 Reduced DGD Purification
Another activating column was run to ensure that the enzyme was loaded up with the 
cofactor, PLP (see section 2.1.e for method). Then, the cofactor-bound DGD was 
reduced by sodium borohydride to form a covalent bond between the cofactor and the 
enzyme. The covalent bond will not break when the enzyme is analyzed by HPLC and/or 
LC/MS/MS. This allows the amino acid site of attachment of the PLP to be studied.
First, a total of 7 mg of purified DGD was injected onto the column and eluted in 1 
mL fractions with potassium phosphate buffer. The three fractions containing the most 
amount of protein were combined and reduced with 5 mg of sodium borohydride at room 
temperature for 1 h. The reaction produced a significant amount of bubbles due to the 
production of hydrogen gas. The combined fractions were analyzed by taking the 
absorbance at 595 nm of 10 pL of the reduced protein solution mixed with 1.5 mL of 
Bradford Reagent.
Next, 3 mL of reduced DGD was injected onto another activating column as 
described above. This time 50 mM potassium phosphate buffer pH 7.9 was used to elute 
the protein in 1 mL fractions. After all of the fractions were collected, 15 pL of each 
fraction were put into 1.5 mL of Bradford Reagent, and the absorbances were taken at 
595 nm. The fractions with the highest concentration of protein were combined and 
stored at -70 °C for further experimentation.
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2.3 Digestion Conditions
DGD can be cleaved into several peptides by trypsin. If the enzyme was not cleaved, 
the HPLC would produce a chromatogram with only one peak; however, there are several 
peaks after digestion of the enzyme which can be collected and analyzed by MS. The 
same scenario would take place in LC/MS/MS. Thus, cleavage is useful to study an 
enzyme at the amino acid level.
Several tryptic digest reactions were run to determine the optimal concentration of 
trypsin required to cleave DGD. The lowest amount of trypsin should be used so that the 
enzyme does not get over digested. Five reactions were run with 1 mg of purified DGD 
each, approximately 71 pL. L-l-tosylamide-2-phenylethyl chloromethyl ketone (TPCK) 
trypsin from Sigma was added at 0, 10, 20, 30, or 40 % of the protein concentration. 
Trypsin, 2.0mg, was dissolved in 0.5 mL of 0.05 M Tris HC1 pH 6.8. The reaction was 
allowed to run for 21 h at 37 °C with gentle shaking after which an SDS-PAGE gel was 
run (see section 2.1.d.for method)
After an optimal percent of trypsin to enzyme was determined, another experiment 
was run to determine if the reduced form of DGD could also be digested by trypsin in the 
same manner. Prior to digestion, 1 mL of the reduced enzyme was concentrated using a 
Centricon-30 Concentrator in a 50 mL centrifuge tube. This was done to remove 
contaminants in the buffer solution. The sample was spun at 5,000 RPM for 20 min 
three times to concentrate the reduced enzyme. The final concentration of the reduced 
DGD was 6.1 mg/mL with 90 pL of the protein. Thus, 0.55 mg of protein remained. The
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digestion reaction was allowed to run for 21 h at 37 °C with gentle shaking. Another 
SDS-PAGE gel was run according to the conditions in section 2.1.d.
After the analysis of the DGD and reduced DGD samples, the enzyme was reacted 
with the R (+) isomer of F3AIB, a mechanism-based suicide inhibitor of DGD. Any 
information that is found from a suicide mechanism-based suicide inhibitor can be 
extrapolated back to the natural substrate because the mechanisms are the same. So if the 
enzyme amino acid that interacts with the inhibitor can be determined, it can be assumed 
that the same amino acid is the attachment site for the natural substrate.
The reactions consisted of 3.5 mg of DGD, 2 mM PLP, 50 mM potassium phosphate 
pH 7.5, and 10 mM of i?-F3AIB, which was the last component added to the reaction.
The total volume was lmL, and the reaction took place at room temperature for a total of 
5 h. The reaction was analyzed by a kinetic assay with a UV spectrophotometer at the 
beginning of the reaction, 2.5 h, and 5 h to ensure the complete inhibition of the enzyme. 
At these time points 100 pL of the reaction was removed and placed into 900 pL of an 
assay solution as described above (Figures 3.6-3.8).
Also, a racemic deuterated inhibitor (F3AIB-d3) was reacted with the enzyme in 
parallel with the protonated inhibitor. This was done for further analysis of the inhibitor 
reaction. The conditions were identical to those described above for the protonated 
inhibitor; however, the inhibitor was used at 20 mM instead of 10 mM because the 
F3AIB-d3 was purified as a racemic mixture. The results are shown in figures 3.6-3.8.
Next, 1 mg of protein was removed from both reactions and placed into two new 
eppendorf tubes. Then, 20% trypsin was added to each reaction and the reactions were
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allowed to shake gently at 37°C for 40 h. At this time, a SDS-PAGE was performed 
(results not shown); however, the digestion reaction was not complete so another 20% 
trypsin was added to each reaction and both reactions were allowed to shake gently at 
37°C for another 66 h. Finally, a SDS-PAGE gel was run according to the conditions 
above (Figure 3.9).
2.4 HPLC
RP-HPLC can be used to separate peptides so that they can be collected and analyzed 
for the amino acid content by MS. The peptides are separated on the HPLC column by 
their hydrophobicity. The more hydrophobic a peptide is, the longer it will stay attached 
to the column. If the DGD peptides are separated by RP-HPLC, they can be analyzed by 
MS for amino acid and possible inhibitor content. The peak from the peptide with the 
inhibitor attached to it would only appear in the chromatogram of the inhibited DGD.
A Beckman chromatography system was used to perform RP-HPLC. The RP-HPLC 
setup consisted of a Beckman 126 solvent module, a Beckman 168 detector, and a 
Beckman 508 Autosampler. The software was Beckman System Gold Version 1.7. The 
column was an Alltech Econosphere C18 5 p., 15 mm x 4.6 mm column. Preceding the 
column was an Alltech 7.5 mm x 4.6 mm column guard. An Ansys back pressure 
flow-through regulator was used to collect peaks without air bubbles. The method 
consisted of a gradient from 0% buffer B to 80% buffer B over 100 min. Then, buffer B 
was returned to 0% over 8 min. The entire HPLC run took 114 min. Buffer A consisted 
of 0.2% formic acid and 2.0% HPLC grade acetonitrile in water. Buffer B consisted of
0.2% formic acid in acetonitrile. The solvents were degassed before they were pumped 
onto the column.
Purified DGD, 2.0 mg, was digested with 4% trypsin for 48 h at 37°C with gentle 
shaking. The reaction was brought up to 1 mL with Tris HC1 pH 7.9 prior to the addition 
of trypsin. Approximately, 200 pi of the sample was injected onto the RP-HPLC with the 
autosampler. Several peaks were collected by hand during the RP-HPLC run. Four of 
these peaks were dried down with a Labconco Centravap system. After that, the samples 
were rehydrated with 100 pL of water and dried down again to remove all of the formic 
acid. Finally, the samples were sent for ESI mass spectroscopy (MS) analysis at the 
University of Washington in St. Louis, MO.
Another tryptic digestion of DGD was performed in tandem with a tryptic digestion 
of an inhibited DGD. Purified DGD, 3.5 mg, was put into each of two eppendorf tubes, 
and each reaction was brought up to 1 mL total volume with water. R (+) isomer of 
F3 AIB was added at 20 mM to the reaction as the last ingredient. The reaction was 
allowed to incubate at room temperature for 1 h. Then, 4% trypsin was added to each 
reaction. The reaction was allowed to shake gently at 37°C for 48 h. Finally, 200 pi of 
each reaction was injected onto a RP-HPLC column as described above with an 
autosampler (Figures 3.10-3.11).
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2.5 LC/MS/MS
An LC/MS/MS works by sending the peptides through a RP-HPLC column which 
separates the peptides based on their hydrophobicity. Then, the peptides are analyzed by
a mass analyzer one at a time based on their mass then the mass to charge ratio is 
determined for the peptide as a whole. Next, the peptides are analyzed by another mass 
analyzer and a mass to charge ratio is determined for the peptide as a whole then another 
mass to charge ratio is determined for the peptide with one or more amino acids cleaved 
at the amide bond by kinetic energy. The difference between the whole peptide and the 
peptide minus one amino acid corresponds to the mass to charge ratio for that amino acid. 
This continues for several cycles. Then, the computer searches for a known peptide 
sequence that uniquely corresponds to the mass to charge ratio for that peptide.
Four samples were sent to the University of Washington in St. Louis, MO for 
LC/MS/MS analysis. The column that was utilized was a proteomic column with a 75 u 
diameter. It was 10 cm in length and packed with WATERS Delta-Pak C l8, 5 u particle, 
and a 300 A pore size. The samples were run by Dr. Ilan Vidavsky (Figures 3.12-3.13).
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Chapter 3 -  Results
3.1 DGD Purification
a. Cell Growth
DGD was purified from plasmid pJKDGD-A2.2 which consists of the DGD gene in 
E. coli. The purification process produced 23.5 g of cells in a white cell pellet grown to a 
final OD 600 of 0.86.
b. Protein Assay
After each sonication period, the protein concentration of the supernatant was 
determined via the Bradford method. After the sonicated cells were centrifuged, the dye 
binding assay showed the protein concentration to be 7.5 mg/mL.
c. Ammonium Sulfate Precipitation and Dialysis
The supernatant of the sonication was then mixed with 3.8 M ammonium sulfate. 
After centrifugation, a soft white pellet was present, and upon resuspension of the pellet 
the solution turned pale yellow. The protein concentration of the dissolved pellet was 
found to be 5.3 mg/mL (Table3.1).
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Table 3.1 -  UV spectrophotometer results of the purification of DGD showing the protein 
concentration after sonication and dialysis.
Sample Volume Used 
(pL)
Protein Concentration 
(mg/mL)
Total Volume 
(mL)
Sonication 2na period 5 4.0 150
Sonication 3ra period 5 5.3 150
Sonication 4tn period 5 6.6 150
Sonication 5tn period 5 8.7 150
Sonication 6in period 5 8.7 150
Sonication supernatant 4 7.5 150
Pellet in dialysis buffer 4 5.3 100
d. Ion-Exchange Chromatography
After purification by ion-exchange chromatography, each 4 mL fraction was analyzed 
for protein concentration through utilization of the Bradford method (see section 2.1 .d for 
column chromatography method). The highest amount of protein was found in column 
fractions 69-71 (Figure 3.1a). Then, these column fractions were analyzed by 
SDS-PAGE for purity as described in section 2.1.d (Figure 3.1b). Since, column 
fractions 69-71 had the highest amount of pure protein they were combined for further 
experimentation.
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Figure 3.1a - Graph of ion-exchange chromatography data which shows that the highest amount of 
protein is in fractions 69-71.
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Figure 3.1b - SDS-PAGE which shows that fractions 69-71 contain the purest DGD.
e. Activating Column
Prior to the concentration of the combined column fractions, scans of DGD with and 
without 2-methylalanine were taken. After the addition of the substrate, the peak at 
approximately 410 nm, characteristic of PLP, disappeared and a peak at 320 nm, 
characteristic of PMP, arose. The scan is shown in figure 3.2.
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Figure 3.2 -  Spectrum scans of DGD without and with 2-methylalanine showing the loss of PLP and 
the production of PMP after the addition of 2-methylalanine.
In addition to the column purification, an activating column was run to load the DGD 
with the cofactor, PLP. Fractions 18-23 contained the highest amount of protein, thus 
these fractions were combined and concentrated to 14 mg/mL with a total volume of 6 
mL. The UV spectra results are summarized in table 3.2.
Table 3.2 -  UV spectrophotometer results of the purification of DGD showing the protein 
concentration after ion-exchange chromatography.
Sample Volume Used (pL) Protein Concentration 
(mg/mL)
Total Volume (mL)
Fractions 18-23 4 5.5 18
Concentrated 2 14.0 6
After fractions 18-23 were combined, a kinetic assay was run on the purified DGD. 
The DGD was found to be active when analyzed by a kinetic assay (Figure 3.3). The 
specific activity was calculated to be 0.00098 pmol/m mg.
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Kinetic Assy of Combined DGD
Time (sec)
Figure 3.3 -  Kinetic assay of combined DGD which shows the loss of pyruvate over time.
3.2 Reduced DGD Purification
A total of 3 mL of protein was collected from the activating column. Utilizing the 
Bradford method and a BSA standard curve as described in sections 2.1 and 3.1, it was 
determined that there was 4.3 mg of protein recovered from the column. By using the 
same technique, it was determined that the second activating column recovered 3.7 mg of 
reduced protein.
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3.3 Digestion Conditions
By digesting DGD with different percentages of trypsin, the optimal percent of DGD 
to trypsin was found to be 20%. Figure 3.4 shows that DGD is almost completely 
digested with 20% trypsin. This sample was split into two eppendorf tubes. One was 
frozen at -70 °C and the other was dried down using a Labconco Centravap system and 
sent to the University of Washington in St. Louis, MO for LC/MS/MS analysis.
1 2 3 4 5 6 7
Figure 3.4 -  SDS-PAGE gel of digested trypsinized DGD which shows that the enzyme is completely 
digested by the lack o f a band that corresponds to DGD. Lane 1: Molecular weight standard broad 
range. Lane 2: 33 pg of DGD. Lane 3: 23 pg of DGD without trypsin, shook at 37°C for 21 h. Lane 
4: 23 pg of DGD with 10% trypsin, shook at 37°C for 21h. Lane 5: 23 pg of DGD with 20% trypsin, 
shook at 37°C for 21h. Lane 6: 23 pg of DGD with 30% trypsin, shook at 37°C for 21h. Lane 7: 23 
pg of DGD with 40% trypsin, shook at 37°C for 21 h.
After an optimal percent of trypsin to DGD was determined, the reduced form of 
DGD was trypsinized in the same fashion with the same amount of trypsin (20%). It was 
concluded that the digestion reaction was complete enough for use in LC/MS/MS since
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most of the band which corresponds to DGD was gone (Figure 3.5). Thus, the reaction 
was split into two eppendorf tubes. One was frozen at -70 °C and the other was dried 
down using a Labconco Centravap system and sent to the University of Washington in St. 
Louis, MO for LC/MS/MS analysis.
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Figure 3.5 -  SDS-PAGE gel of digested trypsinized reduced DGD which shows that the reduced 
enzyme is completely digested by the lack of a band that corresponds to DGD. Lane 1: Molecular 
weight standard broad range. Lane 2: 4 pg of reduced DGD. Lane 3: 6 pg of reduced DGD. Lane 4: 
12 pg of reduced DGD. Lane 5: 1 pg of reduced DGD. Lane 6: 4 pg of reduced DGD with 20% 
trypsin, shook at 37°C for 21h. Lane 7: 6 pg of reduced DGD with 20% trypsin, shook at 37°C for 
21h. Lane 8: 12 pg of reduced DGD with 20% trypsin, shook at 37°C for 21h .
Prior to the digestion of the inhibited enzyme samples, it was imperative to ensure 
that the enzyme was completely inhibited by the inhibitor. Thus, kinetic assays were
performed at time 0, 2.5, 5 h. The results were imported into MS Excel graphs, and are 
shown in figures 3.6-3.8.
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Time (sec) ■ Protonated 
• Deuterated
Figure 3.6 -  Kinetic assay at the beginning of the inhibition reaction showing a healthy enzyme.
DGD-lnhibitor Reactions (t = 2.5 hrs)
Times (sec) - Protonated 
• Deute rated
Figure 3.7 -  Kinetic assay at time 2.5 h which shows that the enzyme is inactivated.
Figure 3.8 -  Kinetic assay at time 5 h which shows that the enzyme is completely inactivated.
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It was concluded from these graphs, that both the protonated and deuterated inhibitors 
had completely inhibited the enzyme.
The SDS-PAGE gel of the protonated and deuterated inhibitor reactions is shown in 
figure 3.9. The reactions were allowed to shake gently for 106 h because the reactions 
were digested very little at 40 h.
1 2 3 4 5 6 7 8 9  10
Figure 3.9 -  SDS-PAGE gel of digested trypsinized inhibited DGD which shows that the inhibited 
enzyme is almost completely digested by the reduction of the band that corresponds to DGD. Lane 1: 
Molecular weight standard broad range. Lane 2: 14 pg of DGD. Lane 3: 7 pg of DGD-F3AIB. Lane 
4: 10.5 pg of DGD-F3AIB. Lane 5: 7 pg of DGD-F3AIB, 40% total trypsin shook at 37°C for a total 
of 106h. Lane 6:10.5 pg of DGD-F3AIB, 40% total trypsin shook at 37°C for a total of 106h. Lane 
7: 7 pg o f DGD-F3AIBdj. Lane 8: 10.5 pg of DGD-F3AIBd3. Lane 9: 7 pg o f DGD-F3AIBd3, 40% 
total trypsin shook at 37°C for a total of 106h. Lane 10: 10.5 pg of DGD-F3AIBd3, 40% total trypsin 
shook at 37°C for a total of 106h.
3.4 HPLC
Figure 3.10 is a chromatogram of 0.7 pg of DGD digested with trypsin. Four of these 
peaks were collected and sent for MS analysis with unsuccessful results due to the lack of 
identification of any peptide (data not shown). There may not have been enough peptide 
to analyze due to a large amount of the peptide being lost to the column which would 
explain the lack of results. Figure 3.11 is a comparison of a chromatogram of 0.7 pg of 
trypsin digested DGD and 0.7 pg of inhibited trypsin digested DGD.
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Figure 3.10 -  RP-HPLC chromatogram of 0.7 pg of digested DGD where each peak represents a 
peptide in DGD.
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Figure 3.11 - RP-HPLC chromatogram of 0.7 pg of digested DGD (top) and 0.7 pg of inhibited 
digested DGD (bottom) which shows similarity between the nonmodified and modified DGD.
After MS analysis, it became apparent that collecting peaks from the RP-HPLC was 
inefficient and non successful. Only one of the four samples sent produced results that 
remotely resembled a DGD peptide (data not shown). In addition, due to the complexity 
of the peptide maps it was extremely difficult to try to determine which peaks were the 
same and which peaks were different when comparing the non inhibited enzyme and the 
inhibited enzyme to each other. Thus, it was decided to finish the experiments using 
LC/MS/MS.
3.5 LC/MS/MS
After LC/MS/MS analysis, it was determined that several peptides were found by the 
instrument that corresponded directly to the known sequence of DGD. Figures 3.12 and 
3.13 show the raw data, and table 3.3 indicates which peptides were identified.
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Figure 3.12 -  LC/MS/MS of DGD trypsinized with 20% trypsin showing the MS of the digestion 
mixture and MS/MS of one peptide, (a) total ion current (b) MS of the ions eluting from 34.85 to 
35.27 m (c) MS/MS of the peak of m/z 680.68.
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Figure 3.13 -  LC/MS/MS of reduced DGD trypsinized with 20% trypsin showing the MS of the 
digestion mixture and MS/MS of one peptide, (a) total ion current (b) MS of the ions eluting from 
34.71 to 35.12 m (c) MS/MS of the peak of m/z 740.2.
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Table 3.3 -  Peptides of DGD resulting from trypsin cutting at Lys and Arg. (X indicates that the 
peptide was identified by LC/MS/MS).
Peptide
Mass Position Peptide Sequence
Found 
in MS of 
DGD
Found 
in MS of 
Reduced 
DGD
1355.6 11-Jan MSLNDDATFWR
360.2 14-Dec NAR
652.39 15-19 QHLVR
1412.69 20-31 YGGTFEPMIIER X
218.15 32-33 AK X X
1086.49 34-43 GSFVYDADGR X X
3229.6 44-74 AILDFTSGQMSAVLGHCHPE IVSVIGEYAGK
2127.14 75-93 LDHLFSGMLSRPVVDLATR X
1166.65 94-104 LANITPPGLDR
1615.86 105-120 ALLLSTGAESNEAAIR X X
349.19 121-123 MAK
517.33 124-128 LVTGK
2689.25 129-154 YEIVGFAQSWHGMTGAAASATYSAGR
2131.14 156-176 GVGPAAVGSFAIPAPFTYRPR X
451.23 177-179 FER
2237.04 180-198 NG A YD YL AELD Y AFDLIDR
3233.68 199-230 QSSGNLAAFIAEPILSSGGIIELPDGYMAALK
478.21 233-236 CEAR
1572.84 237-251 GMLLILDE AQT G V GR X X
1014.45 252-260 TGTMFACQR
1258.69 261-272 DGVTPDILTLSK X X
1953.1 273-292 TLGAGLPLAAIVTSAAIEER X
2627.36 293-316 AHELG YLF YTTH V SDPLP A A VGLR X
828.49 317-323 VLDVVQR X
630.36 324-329 DGLVAR X
762.36 330-336 ANVMGDR
288.2 337-338 LR
946.5 340-347 GLLDLMER X
924.42 348-355 FDCIGDVR X
232.14 356-357 GR
1040.67 358-367 GLLLGVEIVK X
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Table 3.3 continued- Peptides of DGD resulting from trypsin cutting at Lys and Arg. (X indicates 
that the peptide was identified by LC/MS/MS).
290.15 368-369 DR
248.16 371-372 TK
857.44 373-381 EPADGLGAK X
389.25 382-384 ITR
2366.15 385-406 ECMNLGLSMNIVQLPGMGGV FR
2649.43 407-431 IAPPLTVSEDEIDLGLSLLGQAIER
203.14 432-433 AL
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Chapter 4 -  Discussion 
4.1 Purpose of the Project
The question addressed by this project was: “can we use mass spectroscopy to verify 
the location of the B6 cofactor, pyridoxal 5’-phosphate (PLP) cofactor and the amino acid 
sequence of the, 2,2-dialkylglycine decarboxylase (DGD)”? The approach used to 
answer this question was to digest unmodified and modified DGD with trypsin, and then 
use LC/MS/MS to compare covalently modified (PLP or F3 AIB) enzyme with the 
unmodified enzyme enabling the identification of the peptide of interaction. Because of 
the significant mass difference between the PLP cofactor and the F3 AIB inhibitor, one 
should be able to use LC/MS/MS to determine whether or not the inhibitor binding site is 
the same as the PLP binding site.
The reason that DGD was used was because this is a unique enzyme that can both 
decarboxylate and transaminate amino acid substrates. Also, DGD is a well studied 
enzyme which is useful because the results of the amino acid content found by 
LC/MS/MS could be compared back to the known sequence.
4.2 Tryptic Digestions
Many trypsin reactions of DGD and reduced DGD were performed to determine the 
optimal percent of trypsin and the time required to digest the enzyme. The DGD enzyme 
was easily digested in 21 h at 37°C as shown by SDS-PAGE. The smallest amount of 
trypsin required to digest the enzyme was 20%. It was found that urea did not speed up
the digestion reaction. Although 10% trypsin partially digested the enzyme, 20% trypsin 
provided a more complete digestion. The reduced enzyme was significantly harder to 
digest. After several attempted digestion reactions were performed on the reduced 
enzyme; I concluded that there was an impurity in the reaction solution that was 
inhibiting the cleavage of the enzyme by trypsin. This impurity may be the sodium from 
the sodium borohydride which changes the confirmation of DGD and results in enzyme 
inhibition (see section 1.5). The change in confirmation may result in less accessible 
cleavage sites for trypsin. Thus, the enzyme was concentrated to try to remove the 
inhibiting impurity along with some of the buffer. A smaller reaction volume was 
desired so that the collisions between the enzyme and the trypsin would be greater. 
Concentrating the enzyme did allow the tryptic digest to occur in 21 h similar to the 
digestion conditions of the non-reduced form of DGD.
The F3AIB-inhibited enzyme from reaction with both protonated and deuterated 
inhibitor took many more hours to cleave with trypsin than the reduced enzyme. After, a 
40 h reaction with 20% trypsin, the F3AIB-inhibited enzyme complex was not nearly 
digested enough for analysis as shown by SDS-PAGE. Thus, the reaction was allowed to 
continue for another 66 h with an additional 20% trypsin. Finally, after the 106 h, the 
F3AIB-inhibited enzyme complex was almost completely digested. The explanation for 
the increased time may be that the inhibitor is tightly bound to the active site of the 
enzyme which stabilizes the structure. In this confirmation the inhibitor blocks the active 
site, making the interior of the enzyme less accessible to the trypsin. One of the reasons 
that the structure may be more stable with the inhibitor in the active site is due to tighter
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interactions between the two monomers. Since the active sites share residues from both 
monomers, the addition of the inhibitor may provide further cross links between the 
monomers. This would form a very tight interaction between the two monomers which 
would greatly inhibit proteolytic action.
4.3 HPLC
After much work with the HPLC, it became apparent that LC/MS/MS could produce 
better, more efficient results. In my hands, the C l8 column from Alltech did not resolve 
the peaks from the tryptic digestion of DGD well enough to collect and analyze the peaks 
with good results. The peaks that did come off of the column were very close together 
which made it very difficult to collect one peak at a time. This resulted in impure 
collections. This problem became apparent after sending four HPLC collected peaks out 
for MS analysis. Of these, only one of them produced an amino acid sequence that 
matched the known peptides in DGD. Thus, it became clear that LC/MS/MS would 
result in better data.
Although the HPLC results did not provide an answer to the main question, the 
chromatograms were reproducible and useful in making it clear that the DGD and the 
F3 AIB-DGD complex did not have the same chromatograms after tryptic digestion.
These results indicated that the F3 AIB was changing the enzyme and that the change was 
not reversible even after the modified enzyme was cleaved into peptides. This is a strong 
indication that the inactivation reaction is a covalent attachment of the inhibitor.
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4.4 LC/MS/MS
LC/MS/MS is a very useful technique for identifying peptides in a mixture of protein 
enzymatic digests. The LC/MS/MS instrument can measure the mass of a peptide to the 
nearest milliamu. If the mass differs by more than one mass unit, it probably does not 
correspond to the predicted peptide. This is important when a protein containing a lot of 
peptides is being analyzed. If several of the masses of the peptides are close, mass 
spectroscopy can distinguish between them. This concept is crucial to the LC/MS/MS 
results reported here.
LC/MS/MS works by injecting a tryptic digest of a protein onto a small Cl 8 column 
which separates the peptides with high resolution. Then, the column eluate is sprayed 
into the source of the mass analyzer, where each droplet of solvent is evaporated off of 
the peptide. Finally, each peptide is accelerated through the magnetic field to measure its 
mass. If the peptide is abundant, it is then selected, fragmented by collision with inert 
gas atoms, and analyzed for the masses of the constituent peptide fragments, hence the 
term MS/MS. This results in an accurate sequence for each peptide. After the sequence 
is known, the “Mascot” software is used to identify known proteins that have that 
particular peptide. If the sequence of the protein is already known, the experimental 
results can then be compared to the theoretical results. If the peptide is not abundant, the 
spectrometer does not further analyze it. The “Mascot” software will try to match that 
mass to any peptide that has that mass. Thus, the user would have to determine what that 
mass corresponds to.
Based on the sequence of DGD, cleavage of DGD with trypsin should result in 43
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peptides (Table 3.3). Upon LC/MS/MS analysis of the trypsinized DGD, only eight of 
these peptides where identified (Table 3.3). One peptide was identified as 
DGVTPDILTLSK which corresponds to an active site peptide that contains lysine 272. 
This is the lysine that has been identified as having PLP bound to it upon reduction.(3) 
Thirteen peptides were identified by the LC/MS/MS analysis of the trypsinized reduced 
DGD (Table 3.3). There were more peptides identified in the reduced concentrated 
sample probably because the reduction reaction makes the enzyme looser and more 
accessible to trypsin.
Upon analysis of the peptides that were in low abundance, a peptide with m/z equal to 
1491.64 amu was identified. This is the mass that would be expected if PLP was bound 
to a tryptic peptide containing lysine 272, i.e. DGVTPDILTLSK. This peptide has a 
mass of 1258.69 amu, and the mass of a bound PLP was found by Chen and Frey to be 
231.14 amu(25). Since the C-N bond is reduced, 2 amu would be added resulting in a 
mass of 1491.83. This mass was not found in the nonreduced sample. The reason that 
this adduct was found in low abundance is because the reduction of DGD was not 
performed at an optimal pH. Sodium borohydride is stable in basic conditions; however, 
in this case sodium borohydride was added to a mixture at pH 7. Consequently, a large 
portion of sodium borohydride most likely decomposed prior to reducing the PLP-peptide 
bond. The observation of an excessive amount of bubbles, hydrogen release, supports 
this conclusion. This would lead to the presence of the peptide containing lysine 272 
with and without the bound cofactor, each in low abundance. Also, the decomposition of 
sodium borohydride could account for the presence of sodium which is an inhibitor of
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DGD (Section 1.5). The presence of sodium would change the conformation of the 
enzyme and reduce the action of trypsin. Hence, the reduced sample would be protected 
from cleavage by trypsin. Since the peptide containing lysine 272 was found with and 
without PLP and there was an impurity in the reduced sample that could not be accounted 
for in the nonreduced sample, I conclude that the reduction reaction was incomplete.
4.5 Future Experiments
In the future, the F3 AIB-DGD samples will be analyzed by LC/MS/MS. Because the 
inhibited enzyme was more difficult to digest, it is likely that there will be fewer peptides 
identified by LC/MS/MS. One way to avoid this pitfall would be to digest the inhibited 
samples for a longer period of time using even more trypsin. For this sample, one would 
look for a mass of 1258.69 amu which corresponds to the peptide containing lysine 272, 
DGVTPDILTLSK, with the addition of the mass of the inhibitor, the mass of the peptide 
immediately following lysine 272, and possibly the mass of PLP. The reason that one 
would look for the mass of the peptide immediately following lysine 272, 
TLGAGLPLAAIVTSAAIEER (mass=1953.10), in addition to the mass of the peptide 
containing lysine 272 is because if lysine 272 were bound to the inhibitor, trypsin would 
no longer recognize it as a cut site. Since it is not known if PLP stays bound to the lysine 
upon reaction with the inhibitor, one would look for the mass of the two peptides bound 
together with the inhibitor with and without the mass of PLP. The resulting mass would 
reveal the chemistry behind this reaction.
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